TS-005730 — This novel rapid‑cannulation device and technique is designed to significantly reduce the time required to initiate extracorporeal membrane oxygenation during emergency ECMO‑assisted cardiopulmonary resuscitation (E‑CPR).

TS-005703 — This unique IP is a youth digital health intervention program designed to support families of childhood cancer survivors aged 3 to 6, delivered through a web‑based library of responsive‑parenting modules paired with weekly live coaching sessions over three months.

TS-005688 — This IP is a transition‑planning toolkit, delivered as an application or website, designed to support children who use augmentative and alternative communication (AAC) as they move from pediatric therapy into adult‑based services and community programs.

TS-005641 — This new composition of matter is a Intranasal multivalent vaccine candidates for both SARS-CoV-2 and RSV. This vaccine platform uses attenuated measles (MeV) and mumps (MuV) virus vectors to deliver optimized SARS‑CoV‑2 and RSV antigens. The intranasal multivalent vaccine was developed in response to the ongoing challenges posed by rapidly evolving COVID‑19 variants and the lack of effective RSV vaccines for infants and children.

TS-005639 — Researchers have discovered a new opportunity to develop bio markers for brain disorders. New findings suggest that serine/theronine (o-linked) glycoproteins in the brain are uniquely vulnerable to epilepsy-causing SLC35A2 mutations. This work is focused on the identification and monitoring of children with SLC35A2-associated epilepsy. The findings can be applied in several settings, including the use of Western blot and immunofluorescence analysis of t‑aGalNAc levels from brain biopsies as diagnostic tools, as well as the development of highly sensitive biomarker assays using mass spectrometry to measure brain‑specific t‑aGalNAc in CSF, plasma or serum, urine, and extracellular vesicles.

TS-005618 —

TS-005572 — This novel gene replacement strategy uses an adeno-associated viral vector to treat Cockayne syndrome type B (CSB). CSB is a rare neurodegenerative disorder caused by mutations in the ERCC6 or ERCC8 genes, both of which are responsible for DNA repair, causing tremors, ataxia, seizures, and cachectic dwarfism, significantly impacting their quality of life. An AAV-based gene replacement therapy will effectively combat this disorder by delivering a functional copy of the defective gene into target cells, thereby restoring normal gene expression.

TS-005571 — This new urine‑based biomarker panel is specialized for the early, non‑invasive detection and monitoring of obstructive uropathy (OU), a condition that results from anatomical or functional urinary tract obstruction due to congenital causes. Despite the clinical importance of OU, there are currently no validated non-invasive biomarkers that can successfully detect early parenchymal injury, predict disease progression, or guide therapeutic intervention in obstructive nephropathy. These non-invasive biomarkers combine the urinary proteomics with single-cell transcriptomics from the urinary tract and kidney, allowing the identification and tracing of novel biomarkers to their cellular origins and the mapping of specific sites, leading to interventions to stabilize kidney and bladder function and prevent further deterioration and promote recovery.

TS-005570 — A new way of using cardiac myosin activators can be used to treat underactive urinary bladder. Poor urinary bladder contraction, which affects millions of individuals, can be caused by many diseases and has no effective treatments. By repurposing existing cardiac myosin MYH7-activating drugs and designing new myosin-binding ligands, clinicians can improve detrusor smooth muscle (dSM) myosin MYH11 contraction. With this redesigned drug, clinicians can target smooth muscle myosin MYH11 to improve the contraction of visceral muscle.

TS-005569 — This novel cerebral shunt device is designed to treat hydrocephalus using an improved continuous drainage of cerebrospinal fluid and preventing blockages. Constructed from flexible, biocompatible materials, the design includes features for aspiration, anchoring, and modular valve control to enhance reliability and safety. This device is able to reverse flow or apply pressure to clear obstructions using an inner and outer tube system with a built-in pump unit.